Oncology Institute (NASDAQ:TOI) Major Shareholder Buys $136,345.00 in Stock

The Oncology Institute, Inc. (NASDAQ:TOI) major shareholder Jorey Chernett purchased 33,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were acquired at an average cost of $4.07 per share, with a total value of $136,345.00. Following the completion of the purchase, the insider directly owned 10,567,858 shares in the company, valued at $43,011,182.06. The trade was a 0.32% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Tuesday, May 19th, Jorey Chernett purchased 5,000 shares of Oncology Institute stock. The shares were acquired at an average cost of $4.05 per share, with a total value of $20,250.00.
• On Tuesday, May 19th, Jorey Chernett bought 30,000 shares of Oncology Institute stock. The shares were purchased at an average cost of $4.09 per share, with a total value of $122,700.00.
• On Thursday, April 9th, Jorey Chernett purchased 20,000 shares of Oncology Institute stock. The shares were purchased at an average price of $3.10 per share, for a total transaction of $62,000.00.
• On Tuesday, March 24th, Jorey Chernett acquired 125,000 shares of Oncology Institute stock. The stock was bought at an average cost of $3.11 per share, with a total value of $388,750.00.
• On Friday, March 20th, Jorey Chernett bought 25,000 shares of Oncology Institute stock. The shares were purchased at an average cost of $3.35 per share, with a total value of $83,750.00.
• On Tuesday, March 17th, Jorey Chernett purchased 75,000 shares of Oncology Institute stock. The shares were bought at an average price of $3.42 per share, for a total transaction of $256,500.00.
• On Monday, March 16th, Jorey Chernett acquired 60,985 shares of Oncology Institute stock. The stock was acquired at an average price of $3.29 per share, with a total value of $200,640.65.
• On Friday, March 13th, Jorey Chernett purchased 263,000 shares of Oncology Institute stock. The shares were purchased at an average price of $2.92 per share, with a total value of $767,960.00.

Oncology Institute Trading Down 0.8%

NASDAQ:TOI traded down $0.04 during midday trading on Thursday, reaching $4.17. The company had a trading volume of 358,184 shares, compared to its average volume of 1,889,279. The Oncology Institute, Inc. has a 12-month low of $2.02 and a 12-month high of $4.88. The firm has a market capitalization of $411.67 million, a price-to-earnings ratio of -11.28 and a beta of 0.33. The stock’s fifty day simple moving average is $3.43 and its 200-day simple moving average is $3.32.

Oncology Institute (NASDAQ:TOI) last posted its earnings results on Thursday, May 7th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The firm had revenue of $147.44 million for the quarter, compared to analyst estimates of $142.10 million. As a group, sell-side analysts expect that The Oncology Institute, Inc. will post -0.2 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on TOI. Needham & Company LLC reissued a “buy” rating and set a $5.00 price target on shares of Oncology Institute in a research note on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a report on Monday, April 20th. B. Riley Financial upped their price objective on Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Finally, BTIG Research restated a “buy” rating and set a $7.00 price objective on shares of Oncology Institute in a report on Monday, March 9th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Oncology Institute currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Hedge Funds Weigh In On Oncology Institute

A number of large investors have recently bought and sold shares of the business. Kestra Advisory Services LLC acquired a new stake in shares of Oncology Institute in the fourth quarter valued at approximately $31,000. Pekin Hardy Strauss Inc. acquired a new position in Oncology Institute in the fourth quarter worth approximately $36,000. Cetera Investment Advisers boosted its stake in Oncology Institute by 35.0% in the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after purchasing an additional 4,545 shares during the period. State of Wyoming acquired a new position in Oncology Institute in the 2nd quarter worth approximately $37,000. Finally, R Squared Ltd acquired a new position in Oncology Institute in the 4th quarter worth approximately $41,000. Institutional investors own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.